MA56449A - Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine - Google Patents

Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Info

Publication number
MA56449A
MA56449A MA056449A MA56449A MA56449A MA 56449 A MA56449 A MA 56449A MA 056449 A MA056449 A MA 056449A MA 56449 A MA56449 A MA 56449A MA 56449 A MA56449 A MA 56449A
Authority
MA
Morocco
Prior art keywords
rilpivirine
methods
pediatric patients
treating hiv
hiv
Prior art date
Application number
MA056449A
Other languages
English (en)
Inventor
Herta Crauwels
Eygen Veerle Van
Simon Vanveggel
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56449A publication Critical patent/MA56449A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056449A 2019-07-03 2020-07-02 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine MA56449A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03

Publications (1)

Publication Number Publication Date
MA56449A true MA56449A (fr) 2022-05-11

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056449A MA56449A (fr) 2019-07-03 2020-07-02 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
MA056453A MA56453A (fr) 2019-07-03 2020-07-03 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA056453A MA56453A (fr) 2019-07-03 2020-07-03 Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Country Status (13)

Country Link
US (3) US20210000823A1 (fr)
EP (2) EP3993799A1 (fr)
JP (2) JP2022538338A (fr)
KR (2) KR20220028049A (fr)
CN (2) CN114126655A (fr)
AU (2) AU2020300818A1 (fr)
BR (2) BR112021026916A2 (fr)
CA (2) CA3144534A1 (fr)
IL (1) IL289457A (fr)
JO (1) JOP20210347A1 (fr)
MA (2) MA56449A (fr)
MX (2) MX2022000060A (fr)
WO (2) WO2021001508A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ME01980B (fr) * 2010-11-19 2015-05-20 Gilead Sciences Inc Compositions thérapeutiques comprenant un hydrochlorure de rilpivirine et un fumarate de ténofovir disoproxil
CA2921336A1 (fr) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Formulations pharmaceutiques
US12011506B2 (en) * 2017-06-30 2024-06-18 Viiv Healthcare Company Combination and uses and treatments thereof

Also Published As

Publication number Publication date
KR20220028048A (ko) 2022-03-08
EP3993799A1 (fr) 2022-05-11
KR20220028049A (ko) 2022-03-08
US20220313693A1 (en) 2022-10-06
CN114080223A (zh) 2022-02-22
MX2021015627A (es) 2022-04-25
CA3144534A1 (fr) 2021-01-07
IL289457A (en) 2022-02-01
JP2022538449A (ja) 2022-09-02
JP2022538338A (ja) 2022-09-01
MX2022000060A (es) 2022-04-18
AU2020300033A1 (en) 2022-02-24
US20240139186A1 (en) 2024-05-02
WO2021001568A1 (fr) 2021-01-07
AU2020300818A1 (en) 2022-03-03
BR112021026739A2 (pt) 2022-04-26
WO2021001508A1 (fr) 2021-01-07
EP3993800A1 (fr) 2022-05-11
CN114126655A (zh) 2022-03-01
JOP20210347A1 (ar) 2023-01-30
MA56453A (fr) 2022-05-11
BR112021026916A2 (pt) 2022-05-10
US20210000823A1 (en) 2021-01-07
CA3144307A1 (fr) 2021-01-07

Similar Documents

Publication Publication Date Title
FR24C1024I1 (fr) Combinaisons du dolutégravir et de la lamivudine destinées au traitement de l'infection au vih
WO2018115507A3 (fr) Vaccin contre l'hénipavirus
MA45550A (fr) Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA48480A (fr) Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
WO2014176128A3 (fr) Compositions et méthodes pour le traitement et le diagnostic de la grippe
MA51918A (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
AR076570A1 (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
PH12017550023A1 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
HK1250629A1 (zh) 用於治療人乳頭狀瘤病毒皮膚感染的含乙酰水楊酸的組合物和醫療裝置
BR112017024212A2 (pt) sequências de uricases melhoradas e métodos de tratamento
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
WO2016029136A8 (fr) 3-amidobenzamides et leurs utilisations pour augmenter les taux cellulaires d'a3g
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
AR106057A1 (es) Composición con efecto antiviral, composición farmacéutica
IL286386A (en) Methods for treating negative symptoms of schizophrenia using dextromethorphan and quinidine with deuterium
MA56453A (fr) Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
MA55515A (fr) Procédés de traitement de la dystrophie musculaire avec casimersen
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза